Equities analysts expect that Beyondspring Inc (NASDAQ:BYSI) will post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Beyondspring’s earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.30). Beyondspring reported earnings of ($0.61) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 36.1%. The firm is expected to report its next earnings results on Tuesday, October 22nd.
On average, analysts expect that Beyondspring will report full year earnings of ($1.54) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.24). For the next financial year, analysts expect that the company will post earnings of $0.23 per share, with EPS estimates ranging from ($1.26) to $1.72. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Beyondspring.
Beyondspring (NASDAQ:BYSI) last announced its earnings results on Wednesday, September 18th. The company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.05).
BYSI traded down $0.63 during trading hours on Wednesday, reaching $17.20. 60,755 shares of the company’s stock traded hands, compared to its average volume of 48,756. The firm has a 50-day moving average price of $17.78 and a 200 day moving average price of $17.38. Beyondspring has a 52-week low of $13.06 and a 52-week high of $26.86. The firm has a market capitalization of $397.79 million, a PE ratio of -7.11 and a beta of 1.30.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Beyondspring during the 2nd quarter valued at about $11,904,000. Vanguard Group Inc. purchased a new stake in Beyondspring during the 2nd quarter valued at about $956,000. Northern Trust Corp purchased a new stake in Beyondspring during the 2nd quarter valued at about $720,000. Charles Schwab Investment Management Inc. purchased a new stake in Beyondspring during the 2nd quarter valued at about $528,000. Finally, Bank of New York Mellon Corp purchased a new stake in Beyondspring during the 2nd quarter valued at about $516,000. Institutional investors and hedge funds own 5.27% of the company’s stock.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Recommended Story: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.